{"page":{"totalFilteredElements":347},"studies":[{"active":true,"description":"Nationales Netzwerk Genomische Medizin Lungenkrebs nNGM","eudractNumber":null,"id":4357,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[],"nctNumber":"NCT05934032","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2018-01-01T10:03:00+01:00","shortTitle":"Nationales Netzwerk Genomische Medizin Lungenkrebs nNGM","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Preoperative radiotherapy versus postoperative radiotherapy after neoadjuuvant chemotherapy (\"NeoRad\") in high-risk breast cancer: a prospective, randomized, international, multicenter Phase III trial","eudractNumber":null,"id":10183,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT04261244","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-07-02T09:29:26+02:00","shortTitle":"NeoRad","therapeutical":true,"therapyLines":[{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"2- and 5-year neuropsychological follow-up of young\nchildren with medulloblastoma, CNS-PNET and ependymoma treated within the prospective\nmulticenter trial HIT 2000 SKK<br /><br />Geplante Laufzeit: 01.07.2013 - 31.03.2017<br />","eudractNumber":null,"id":964,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2013-07-01T13:26:27+02:00","shortTitle":"Neuropsychological diagnostics in HIT 2000 SKK","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Treatment and outcome of patients with advanced breast cancer: clinical research platform for real world data (OPAL)&#160;<b>IOM-100361</b>","eudractNumber":null,"id":4638,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT03417115","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-05-03T12:36:45+02:00","shortTitle":"OPAL (IOM-100361)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<p class=\"MsoNormal\">A Phase 2, Open-Label, Parallel Cohort Study of\nSubcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or\nMetastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer [CR109264]</p>","eudractNumber":"2022-000526-21","id":8484,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"EGFR","id":"mt_1"}],"nctNumber":"NCT05498428","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-03-01T11:55:23+01:00","shortTitle":"PALOMA-2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Patientendatenintegrationsplattform der Pancreatic Cancer Alliance Bavaria (PCAB)","eudractNumber":null,"id":10521,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2023-05-26T12:31:40+02:00","shortTitle":"PCAB (Pankreasregister)","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<div><br /></div><div>DRKS00010774<br /></div>","eudractNumber":null,"id":9703,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-03-15T08:27:15+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<br /><div><br /></div><div>DRKS00010774<br /></div>","eudractNumber":null,"id":10857,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-04-01T08:48:22+02:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<br /><div><br /></div><div>DRKS00010774</div>","eudractNumber":null,"id":4307,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2017-01-03T12:47:13+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<br /><div><br /></div><div>DRKS00010774</div>","eudractNumber":null,"id":10618,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-08-05T09:22:14+02:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]}]}